Pay in 4 interest-free payments of $7.10 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
The most common treatment-emergent AEs were gastrointestinal in nature and mostly mild in severity
PMID: 38963021
Anyone taking medications for diabetes, thyroid disorders, or other metabolic conditions should consult a healthcare provider before starting AOD-9604 to assess potential interactions and ensure appropriate monitoring
Long-term Results: According to 2026 data, patients on tirzepatide or semaglutide often reach their peak weight loss between month 10 and month 14 . Total Loss: Most successful patients see a total reduction of 15% to 22% of their starting weight by the one-year mark. The Shift: At this stage, you and your doctor will discuss whether to stay on a "maintenance" dose or begin a very slow taper, depending on your metabolic health goals
US$ 27.25
US$ 28.73
US$ 28.22
